ReviewStem cells translational medicine2012
Concise review: pancreas regeneration: recent advances and perspectives.
Review in Stem cells translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Promoting β-cells function by the recapitulation of in vivo microenvironmental differentiation signals.Cell and tissue research · 2023Article
- Effect of kolaviron on islet dynamics in diabetic rats.Saudi journal of biological sciences · 2022Article
- The potential and challenges of alternative sources of β cells for the cure of type 1 diabetes.Endocrine connections · 2018Review
- Prevention of glucocorticoid-associated osteonecrosis by intravenous administration of mesenchymal stem cells in a rabbit model.BMC musculoskeletal disorders · 2017Article
- Modeling psychiatric disorders: from genomic findings to cellular phenotypes.Molecular psychiatry · 2016Review
- β-cell replacement sources for type 1 diabetes: a focus on pancreatic ductal cells.Therapeutic advances in endocrinology and metabolism · 2016Review
- Progenitor cell niches in the human pancreatic duct system and associated pancreatic duct glands: an anatomical and immunophenotyping study.Journal of anatomy · 2016Article
- Growth factors and medium hyperglycemia induce Sox9+ ductal cell differentiation into β cells in mice with reversal of diabetes.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Article
- An optimised mouse model of chronic pancreatitis with a combination of ethanol and cerulein.Central-European journal of immunology · 2016Article
- Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies.BMC medicine · 2015Review
- Repurposed biological scaffolds: kidney to pancreas.Organogenesis · 2015Article
- The ACE2/Ang-(1-7)/Mas Axis Regulates the Development of Pancreatic Endocrine Cells in Mouse Embryos.PloS one · 2015Article
- Development of an encapsulated stem cell-based therapy for diabetes.Expert opinion on biological therapy · 2015Review
- Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives.World journal of diabetes · 2014Review
- β-Cell differentiation of human pancreatic duct-derived cells after in vitro expansion.Cellular reprogramming · 2014Article
- Loss of Fbw7 reprograms adult pancreatic ductal cells into α, δ, and β cells.Cell stem cell · 2014Article
- Concise review: pluripotent stem cell-based regenerative applications for failing β-cell function.Stem cells translational medicine · 2014Review
- The potential of cell-based therapy for diabetes and diabetes-related vascular complications.Current diabetes reports · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The replacement of functional pancreatic β-cells is seen as an attractive potential therapy for diabetes, because diabetes results from an inadequate β-cell mass. Inducing replication of the remaining β-cells and new islet formation from progenitors within the pancreas (neogenesis) are the most direct ways to increase the β-cell mass. Stimulation of both replication and neogenesis have been reported in rodents, but their clinical significance must still be shown. Because human islet transplantation is limited by the scarcity of donors and graft failure within a few years, efforts have recently concentrated on the use of stem cells to replace the deficient β-cells. Currently, embryonic stem cells and induced pluripotent stem cells achieve high levels of β-cell differentiation, but their clinical use is still hampered by ethical issues and/or the risk of developing tumors after transplantation. Pancreatic epithelial cells (duct, acinar, or α-cells) represent an appealing alternative to stem cells because they demonstrate β-cell differentiation capacities. Yet translation of such capacity to human cells after significant in vitro expansion has yet to be achieved. Besides providing new β-cells, cell therapy also has to address the question on how to protect the transplanted cells from destruction by the immune system via either allo- or autoimmunity. Encouraging developments have been made in encapsulation and immunomodulation techniques, but many challenges still remain. Herein, we discuss recent advances in the search for β-cell replacement therapies, current strategies for circumventing the immune system, and mandatory steps for new techniques to be translated from bench to clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.